Therapeutic effects of resveratrol in Escherichia coli-induced rat endometritis model

2019 ◽  
Vol 392 (12) ◽  
pp. 1577-1589 ◽  
Author(s):  
Murside Ayse Demirel ◽  
Sevtap Han ◽  
Aytekin Tokmak ◽  
Nilufer Ercan Gokay ◽  
Mecit Orhan Uludag ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Therapeutic Effects

Therapeutic Effects of High Molecular Weight Hyaluronic Acid in Severe Pseudomonas Aeruginosa Pneumonia in Ex Vivo Perfused Human Lungs

2021 ◽  
Author(s):  
Xiwen Zhang ◽  
Shinji Sugita ◽  
Airan Liu ◽  
Yoshifumi Naito ◽  
Wonjung Hwang ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Molecular Weight ◽  
Pseudomonas Aeruginosa ◽  
Hyaluronic Acid ◽  
High Molecular Weight ◽  
Bacterial Pneumonia ◽  
Ex Vivo ◽  
Therapeutic Effects ◽  
Human Lungs ◽  
Protein Permeability

Introduction: We previously reported that extracellular vesicles (EVs) released during Escherichia coli bacterial pneumonia were inflammatory, and administration of high molecular weight hyaluronic acid (HMW HA) suppressed several indices of acute lung injury (ALI) from Escherichia coli pneumonia by binding to these inflammatory EVs. The current study was undertaken to study the therapeutic effects of HMW HA in ex vivo perfused human lungs injured with Pseudomonas aeruginosa (PA)103 bacterial pneumonia. Methods: For lungs with baseline alveolar fluid clearance (AFC)<10%/h, HMW HA 1 or 2 mg was injected intravenously after 1 h (N = 4-9), and EVs released during PA pneumonia were collected from the perfusate over 6 h. For lungs with baseline AFC>10%/h, HMW HA 2 mg was injected intravenously after 1 h (N = 6). In vitro experiments were conducted to evaluate the effects of HA on inflammation and bacterial phagocytosis. Results: For lungs with AFC<10%/h, administration of HMW HA intravenously significantly restored AFC and numerically decreased protein permeability and alveolar inflammation from PA103 pneumonia but had no effect on bacterial counts at 6 h. However, HMW HA improved bacterial phagocytosis by human monocytes and neutrophils and suppressed the inflammatory properties of EVs released during pneumonia on monocytes. For lungs with AFC>10%/h, administration of HMW HA intravenously improved AFC from PA103 pneumonia but had no significant effects on protein permeability, inflammation or bacterial counts. Discussion: In the presence of impaired alveolar epithelial transport capacity, administration of HMW HA improved the resolution of pulmonary edema from Pseudomonas PA103 bacterial pneumonia.

Mechanisms for Lactobacillus rhamnosus treatment of intestinal infection by drug-resistant Escherichia coli

2020 ◽  
Vol 11 (5) ◽  
pp. 4428-4445 ◽  
Author(s):  
Na Li ◽  
Bing Pang ◽  
Junjun Li ◽  
Guanwen Liu ◽  
Xiaoguang Xu ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Lactobacillus Rhamnosus ◽  
Multiple Drug ◽  
Therapeutic Effects ◽  
Drug Resistant ◽  
Intestinal Infection ◽  
E Coli ◽  
Intestinal Integrity ◽  
Multiple Drug Resistant

Reducing the viability of pathogens may also play an important role for the therapeutic effects of Lactobacillus rhamnosus SHA113 against multiple-drug-resistant E. coli, as well as influencing on the intestinal integrity and functions of animals.

scholarly journals Microencapsulated phages show prolonged stability in gastrointestinal environments and high therapeutic efficiency to treat Escherichia coli O157:H7 infection

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Hanjie Yin ◽  
Jing Li ◽  
Haosheng Huang ◽  
Yuxin Wang ◽  
Xinjie Qian ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Phage Therapy ◽  
Severe Disease ◽  
Simulated Gastric Fluid ◽  
Economic Losses ◽  
Therapeutic Effects ◽  
Simulated Intestinal Fluid ◽  
E Coli ◽  
Therapeutic Efficiency

AbstractEscherichia coli (E. coli) O157:H7 bacterial infection causes severe disease in mammals and results in substantial economic losses worldwide. Due to the development of antibiotic resistance, bacteriophage (phage) therapy has become an alternative to control O157:H7 infection. However, the therapeutic effects of phages are frequently disappointing because of their low resistance to the gastrointestinal environment. In this study, to improve the stability of phages in the gastrointestinal tract, E. coli O157:H7 phages were microencapsulated and their in vitro stability and in vivo therapeutic efficiency were investigated. The results showed that compared to free phages, the resistance of microencapsulated phages to simulated gastric fluid and bile salts significantly increased. The microencapsulated phages were efficiently released into simulated intestinal fluid, leading to a better therapeutic effect in rats infected with E. coli O157:H7 compared to the effects of the free phages. In addition, the microencapsulated phages were more stable during storage than the free phages, showing how phage microencapsulation can play an essential role in phage therapy.

Effect of hydrogen peroxide on antibacterial activities of Canadian honeys

2006 ◽  
Vol 52 (12) ◽  
pp. 1228-1237 ◽  
Author(s):  
Katrina Brudzynski
Keyword(s):  
Escherichia Coli ◽  
Hydrogen Peroxide ◽  
Antibacterial Activity ◽  
Bacillus Subtilis ◽  
Specific Activity ◽  
Bacterial Species ◽  
Antibacterial Activities ◽  
Therapeutic Effects ◽  
E Coli ◽  
The Impact

Honey is recognized as an efficacious topical antimicrobial agent in the treatment of burns and wounds. The antimicrobial activity in some honeys depends on the endogenous hydrogen peroxide content. This study was aimed to determine whether honey's hydrogen peroxide level could serve as a honey-specific, activity-associated biomarker that would allow predicting and assessing the therapeutic effects of honey. Using a broth microdilution assay, I analyzed antibacterial activities of 42 Canadian honeys against two bacterial strains: Escherichia coli (ATCC 14948) and Bacillus subtilis (ATCC 6633). The MIC90 and MIC50 were established from the dose-response relationship between antibacterial activities and honey concentrations. The impact of H2O2 on antibacterial activity was determined (i) by measuring the levels of H2O2 before and after its removal by catalase and (ii) by correlating the results with levels of antibacterial activities. Canadian honeys demonstrated moderate to high antibacterial activity against both bacterial species. Both MIC90 and MIC50 revealed that the honeys exhibited a selective growth inhibitory activity against E. coli, and this activity was strongly influenced by endogenous H2O2 concentrations. Bacillus subtilis activity was marginally significantly correlated with H2O2 content. The removal of H2O2 by catalase reduced the honeys' antibacterial activity, but the enzyme was unable to completely decompose endogenous H2O2. The 25%-30% H2O2 "leftover" was significantly correlated with the honeys' residual antibacterial activity against E. coli. These data indicate that all Canadian honeys exhibited antibacterial activity, with higher selectivity against E. coli than B. subtilis, and that these antibacterial activities were correlated with hydrogen peroxide production in honeys. Hydrogen peroxide levels in honey, therefore, is a strong predictor of the honey's antibacterial activity.Key words: honey, antibacterial activity, hydrogen peroxide, catalase, Escherichia coli, Bacillus subtilis.

Curative effects of Distemonanthus benthamianus Baillon. Trunk-bark extracts on enteropathogenic Escherichia coli 31-induced diarrhea in rats

2019 ◽  
Vol 16 (4) ◽  
Author(s):  
Yousseu Nana William ◽  
Ateufack Gilbert ◽  
Abdul Jabbar Shah ◽  
Fazli Wahid ◽  
Mbiantcha Marius ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Serum Level ◽  
Aqueous Extract ◽  
Methanolic Extract ◽  
Negative Control ◽  
Relative Mass ◽  
Enzyme Linked Immunosorbent Assay ◽  
Therapeutic Effects ◽  
Necrosis Factor Alpha ◽  
Epithelial Regeneration

Abstract Background Distemonanthus benthamianus is used in the Western part of Cameroon to treat diarrheal episodes and infections. This study assessed its trunk-bark extracts activity against enteropathogenic Escherichia coli 31 (EPEC 31)-induced diarrhea in rats. Methods Aqueous and methanolic extracts were analyzed through high-performance liquid chromatography (HPLC). In vitro minimum inhibitory and bactericidal concentrations (MICs/MBCs) were evaluated on Enterococcus faecalis (ATCC 10,541), E. coli (ATCC 6539), Klebsiella pneumoniae (ATCC 13,883), Salmonella typhi (ATCC 6539) strains and on Proteus mirabilis, Pseudomonas aeruginosa (PA 01) and Shigella flexneri isolates using the microdilution method. Diarrhea was induced by inoculating rats with EPEC 31 (1.5 × 108 CFU/mL; p.o). Serum transaminases level assay and enzyme-linked immunosorbent assay (ELISA) for cytokines determination were performed. Hematoxylin–eosin (H–E) staining was used for intestinal tissue analysis. Results HPLC fingerprints of extracts showed presence of gallic acid and other unidentified compounds. The lowest MIC of 256 µg/mL was obtained with methanolic extract. At 100 mg/kg, both extracts significantly (p<0.001) inhibited diarrhea, with the methanolic extract being the most active. In addition, the methanolic extract significantly (p<0.001) increased the relative mass of the liver compared to negative control (Tween-DMSO 8%). The aqueous extract (100 mg/kg) significantly (p<0.01) increased alanine aminotransferase (ALT) serum concentration; while the methanolic extract (100 mg/kg) exhibited similar effect over aspartate aminotransferase (AST). At 50 and 100 mg/kg, the methanolic extract significantly (p<0.05 and p<0.01) decreased the Interleukin-1β (IL-1β) serum level, compared to negative control (Tween-DMSO 8%). Serum level of tumor necrosis factor alpha (TNF-α) significantly (p<0.001) decreased with 100 mg/kg of aqueous extract and all doses of methanolic extract. Inhibition of inflammatory cells tissue infiltration and epithelial regeneration was highly noticed in the ileum and colon of extracts-treated rats than in ciprofloxacin-treated animals. Conclusion These findings suggest that D. benthamianus trunk-bark extracts displayed therapeutic effects against infectious diarrhea in rats.

scholarly journals Optimization of fermentation conditions for the production of curcumin by engineered Escherichia coli

2017 ◽  
Vol 14 (133) ◽  
pp. 20170470 ◽  
Author(s):  
Márcia R. Couto ◽  
Joana L. Rodrigues ◽  
Lígia R. Rodrigues
Keyword(s):  
Escherichia Coli ◽  
Plant Secondary Metabolites ◽  
Industrial Scale ◽  
Plant Secondary Metabolite ◽  
Therapeutic Effects ◽  
Heterologous Production ◽  
E Coli ◽  
High Concentrations ◽  
Culturing Conditions ◽  
K 12

Curcumin is a plant secondary metabolite with outstanding therapeutic effects. Therefore, there is a great interest in developing new strategies to produce this high-value compound in a cheaper and environmentally friendly way. Curcumin heterologous production in Escherichia coli using artificial biosynthetic pathways was previously demonstrated using synthetic biology approaches. However, the culturing conditions to produce this compound were not optimized and so far only a two-step fermentation process involving the exchange of culture medium allowed high concentrations of curcumin to be obtained, which limits its production at an industrial scale. In this study, the culturing conditions to produce curcumin were evaluated and optimized. In addition, it was concluded that E. coli BL21 allows higher concentrations of curcumin to be produced than E. coli K-12 strains. Different isopropyl β- d -thiogalactopyranoside concentrations, time of protein expression induction and substrate type and concentration were also evaluated. The highest curcumin production obtained was 959.3 µM (95.93% of per cent yield), which was 3.1-fold higher than the highest concentration previously reported. This concentration was obtained using a two-stage fermentation with lysogeny broth (LB) and M9. Moreover, terrific broth was also demonstrated to be a very interesting alternative medium to produce curcumin because it also led to high concentrations (817.7 µM). The use of this single fermentation medium represents an advantage at industrial scale and, although the final production is lower than that obtained with the LB–M9 combination, it leads to a significantly higher production of curcumin in the first 24 h of fermentation. This study allowed obtaining the highest concentrations of curcumin reported so far in a heterologous organism and is of interest for all of those working with the heterologous production of curcuminoids, other complex polyphenolic compounds or plant secondary metabolites.

scholarly journals COMPARISON OF FOSFOMYCIN TROMETAMOL WITH CIPROFLOXACIN FOR UNCOMPLICATED UTI DUE TO E.COLI IN WOMEN

2015 ◽  
Vol 22 (1) ◽  
Author(s):  
Heri Budiono ◽  
Sunaryo Hardjowijoto ◽  
Tarmono Djojodimedjo ◽  
Doddy M Soebadi ◽  
Agung Dwi Wahyu Widodo ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Single Dose ◽  
T Test ◽  
Therapeutic Effects ◽  
Chi Square ◽  
Dose Therapy ◽  
Fosfomycin Trometamol ◽  
Chi Square Test ◽  
Single Dose Therapy ◽  
Better Than

Objective: To compare clinical therapeutic effects (frequency, dysuria, and pyuria), microbiology, pharmacokinetics index Cmax/MIC Fosfomycin Trometamol 3 gr single dose with Ciprofloxacin 2 x 500 mg/12 hours for 5 days in the treatment of uncomplicated UTI in women due to Escherichia coli (E.Coli). Materials & Methods: Experimental observational design from February until July 2013. Twenty two women with uncomplicated UTI due to E.Coli performed clinical and microbiological examination. Pharmacokinetics index (Cmax/MIC) is looked for. Patients are divided 2 group, Ciprofloxacin 500 mg/12 hours 5 days and Fosfomycin Trometamol single dose. Repeat clinical and microbiological evaluation is performed in 7 days after therapy. Statistic analysis use Chi Square test, Paired T test, and Independent T test. Results: In the treatment of uncomplicated UTI in women, Fosfomycin Trometamol single dose therapy provides clinical cure (dysuria 81.2%, p = 0.338, frequency 90.9%, p = 0.004, pyuria 90.9%, p = 0.009) much better than Ciprofloxacin 500 mg/12 hours 5 days. Fosfomycin Trometamol single dose therapy also provides bacteriological eradication (100%) better than Ciprofloxacin 500 mg/12 hours 5 days (p = 0.035). Fosfomycin Trometamol single dose had a higher pharmacokinetics index (Cmax/MIC) compared to Ciprofloxacin 500 mg/12 hours (p = 0.035). Conclusion: Fosfomycin Trometamol single dose therapy is superior to Ciprofloxacin 500 mg/12 hours 5 days in the treatment of uncomplicated UTI in women. Keywords: Therapeutic effect, fosfomycin trometamol, ciprofloxacin, uncomplicated UTI, Escherichia coli.

Sign in / Sign up

Export Citation Format

Share Document